The Moderna and Pfizer mRNA COVID-19 vaccines have helped significantly reduce the number of cases of COVID-19 since they were first approved for emergency use. Dinendra Haria/SOPA Images/LightRocket via Getty Images
For decades, researchers have dreamed about harnessing the power of genetic technology to prevent or treat a range of diseases. A synthetic version of a molecule in the human body known as messenger RNA (ribonucleic acid), or mRNA, held that promise.
Just
how to make it work presented daunting challenges that much of the science community thought was a mountain too high to climb.
But a handful of researchers didn t give up. They spent years trying to solve the mystery of mRNA. Then, just like a made-for-TV movie, they cracked the code just in time to save the world from the deadly coronavirus pandemic.
JanOne Appoints Internationally Renowned Expert on Addiction Nicholas Goeders, Ph D to Scientific Advisory Board prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
According to the
Mayo Clinic, some 290 million people are infected with malaria annually and at least 400,000 people die of the disease each year predominantly young children, the elderly and the infirm making it the world’s most pervasive parasitic disease. Symptoms involve ongoing cyclical “attacks chills and shivering followed by fevers followed by chills followed by fevers.
“Safe, effective, affordable vaccines could play a critical role in defeating malaria,” Dr Robert Newman, Director of WHO’s
Global Malaria Program said in 2013. ”Despite all the recent progress countries have made, and despite important innovations in diagnostics, drugs and vector control, the global burden of malaria remains unacceptably high.”
Share this article
Share this article
LEXINGTON, Mass., March 16, 2021 /PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter and year ended December 31, 2020. 2020 was a transformative year for Curis, as we made significant progress in our mission to develop the next generation of targeted cancer therapies that meaningfully improve and extend the lives of patients. Despite the difficulties and uncertainty brought about by the ongoing coronavirus pandemic, we significantly advanced and expanded each program in our clinical pipeline, headlined by the very encouraging data from our Phase 1 trials of lead asset, CA-4948, presented in December in conjunction with ASH, said James Dentzer, President and Chief Executive Officer of Curis. We look forward to providing additional updates on our IRAK4 program throughout the year, with